INKT
MiNK Therapeutics Inc

1,713
Mkt Cap
$56.14M
Volume
10,446.00
52W High
$76.00
52W Low
$4.56
PE Ratio
-3.94
INKT Fundamentals
Price
$11.82
Prev Close
$11.96
Open
$11.95
50D MA
$11.98
Beta
0.53
Avg. Volume
20,994.77
EPS (Annual)
-$2.86
P/B
-4.07
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts
Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings...
MarketBeat·15h ago
News Placeholder
More News
News Placeholder
Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to "Hold"
Wall Street Zen raised shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday...
MarketBeat·2d ago
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen cut shares of MiNK Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·10d ago
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·18d ago
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Analysts
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has earned an average rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat reports. One equities...
MarketBeat·26d ago
News Placeholder
Wall Street Zen Downgrades MiNK Therapeutics (NASDAQ:INKT) to Sell
Wall Street Zen downgraded MiNK Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·1mo ago
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of "Hold" from Brokerages
Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are presently covering the stock, Marketbeat reports. One...
MarketBeat·2mo ago
News Placeholder
MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Beats Expectations By $0.21 EPS
MiNK Therapeutics (NASDAQ:INKT - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat·2mo ago
News Placeholder
Analysts Offer Predictions for INKT Q1 Earnings
MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for MiNK Therapeutics in a research note issued on...
MarketBeat·2mo ago
<
1
2
...
>

Latest INKT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.